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Abstract
Background: Mesenchymal stem cells (MSCs) hold great potential as a therapy for stroke and have previously been
shown to promote recovery in preclinical models of cerebral ischaemia. MSCs secrete a wide range of growth
factors, chemokines, cytokines and extracellular vesicles—collectively termed the secretome. In this study, we
assessed for the first time the efficacy of the IL-1α-primed MSC-derived secretome on brain injury and functional
recovery after cerebral ischaemia.
Methods: Stroke was induced in male C57BL/6 mice using the intraluminal filament model of middle cerebral
artery occlusion. Conditioned medium from IL-1α-primed MSCs or vehicle was administered at the time of
reperfusion or at 24 h post-stroke by subcutaneous injection.
Results: IL-1α-primed MSC-derived conditioned medium treatment at the time of stroke led to a ~ 30% reduction
in lesion volume at 48 h and was associated with modest improvements in body mass gain, 28-point neurological
score and nest building. Administration of MSC-derived conditioned medium at 24 h post-stroke led to improved
nest building and neurological score despite no observed differences in lesion volume at day 2 post-stroke.
Conclusions: Our results show for the first time that the administration of conditioned medium from IL-1α-primed
MSCs leads to improvements in behavioural outcomes independently of neuroprotection.
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Background
Stroke is a significant global health problem leading to
around 6.7 million deaths annually [1]. For the 33 mil-
lion people living with stroke, treatment options are very
limited and do not fully alleviate the disability caused
[2]. There is hence a great demand for regenerative ther-
apies to promote repair and improve disability after is-
chaemic stroke.
There is a substantial body of evidence showing that
mesenchymal stem cells (MSCs) improve functional out-
comes in rodent models of cerebral ischaemia, as previ-
ously reviewed by Satani and colleagues [3]. In phase I/II
clinical trials, MSCs have been suggested to be a safe
and feasible therapy for ischaemic stroke [4, 5]. While it
was initially thought that cell replacement was the main
mechanism of action, it has since been shown that most
MSCs become entrapped in the lungs after systemic ad-
ministration and only a small percentage of those that
successfully migrate to the ischaemic brain engraft and
differentiate [6, 7]. More recently, interest has shifted to-
wards the paracrine actions of MSCs, also referred to as
the bystander effect. The MSC secretome has been im-
plicated in promoting recovery by preventing cell apop-
tosis, modulating the inflammatory response and
enhancing endogenous repair mechanisms such as
neurogenesis and angiogenesis [8]. In support of this,
the administration of MSC-derived extracellular vesicles
[9, 10] and conditioned medium (CM) [11–13] has been
shown to improve recovery in rodent models of cerebral
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ischaemia. Clinical application of such acellular ap-
proaches is gaining much interest as potential regenera-
tive therapies as they circumvent the risks of immune
rejection and tumorigenesis associated with cell trans-
plantation [14].
A number of in vitro preconditioning strategies
have been explored to enhance the MSC secretome
including 3D culture [15] and hypoxic precondition-
ing [16]. In our previous work, we clearly demon-
strate that priming with interleukin-1 alpha (IL-1α)
drives the MSC secretome towards a more anti-
inflammatory and pro-trophic phenotype which may
translate into a better therapy for ischaemic stroke
[17]. At present, the effect of such MSC precondition-
ing strategies has not been extensively studied in pre-
clinical models of stroke. Indeed, to the best of our
knowledge, there is only one such study, which
assessed the efficacy of CM derived from hypoxia-
preconditioned MSCs [13] on motor recovery and
neuroprotection in a rat model of ischaemic stroke.
Our previously published in vitro data clearly demon-
strates that IL-1α priming drives MSCs towards a
pro-reparative phenotype. Hence, it is essential to
confirm the benefit of IL-1α priming in a relevant
in vivo paradigm with an extensive characterisation of
the post-stroke behavioural repertoire, as investigated
here in a mouse model of middle cerebral artery
occlusion.
Methods
MSC characterisation
For characterisation, MSCs were stained using the BD
Stemflow™ hMSC Analysis Kit (BD Biosciences, UK) ac-
cording to the manufacturer’s instructions. Cells were
then analysed on a FACSVerse flow cytometer (BD Bio-
sciences, UK) for positive expression of surface markers
CD73, CD90 and CD105 and negative expression of
CD11b, CD19, CD34, CD45 and HLA-DR, as defined by
the International Society for Cellular Therapy as the
minimum criteria for MSCs [18] (Additional file 1: Fig-
ure S1). Positive gates were set using fluorescence minus
one controls. The multipotency of the MSCs was also
assessed using a commercially available kit (R&D Sys-
tems, UK). In brief, MSCs were cultured for 21 days in
differentiation media with media changes every 2–3 days.
Adipocytes were stained with Oil Red O (Millipore, UK),
and osteocytes were stained with Alizarin Red (Milli-
pore, UK). Chrondocyte pellets were cut into 30-μm sec-
tions using a freezing sledge microtome (Bright
Instruments, UK) then stained with toluidine blue
(Sigma-Aldrich, UK). Images were acquired using an
inverted microscope (Olympus CK X31) and a Moticam
2300 camera connected to Motic Images Plus 2.0 ML
software (Motic, Hong Kong).
Mesenchymal stem cell culture
Passage 5–6 human bone marrow-derived MSCs from a
22-week-old foetal donor (3H Biomedical, Sweden) were
used for all experiments. MSCs were cultured as a
monolayer in tissue culture flasks (Corning, UK) in
MesenPRO RS medium (Invitrogen, UK) supplemented
with 1% penicillin/streptomycin and 2mM glutamine.
The growth medium was changed every 4–5 days until
the cells were 70–80% confluent. MSCs were then disso-
ciated with 0.5% trypsin-EDTA (Sigma-Aldrich, UK) and
counted. For IL-1α-primed CM (αCM) preparation,
MSCs were seeded in 6-well plates (Corning, UK) at a
density of 1.75 × 105 cells/well and incubated for 24 h.
MSCs were then treated with 10 ng/ml human recom-
binant IL-1α (R&D Systems, UK) for 5 min. Cells were
washed twice with PBS then serum-free MesenPRO RS
medium (without supplement) was added. After 24 h,
αCM was collected, cell debris was removed using 0.22-
μM syringe filters (Millipore, UK) and 10× concentrated
using 3000 MWCO Vivaspin centrifugal concentrators
(Generon, UK) according to the manufacturer’s instruc-
tions. For the vehicle, serum-free MesenPRO RS
medium was also concentrated 10×. For all in vivo ex-
periments, 400-μl conditioned treatments derived from
3.5 × 105 cells were prepared in advance and stored at −
80 °C.
In vivo experiments
Animals
All animal procedures were carried out in accordance
with the revised Animals (Scientific Procedures) Act
1986, under a Home Office (UK) project licence, and ap-
proved by the local Animal Welfare Ethical Review
Board. Animals were group housed in Sealsafe Plus
Mouse individually ventilated cages (Techniplast, Italy)
at 21 ± 1 °C, 55 ± 10% humidity on a 12-h light-dark
cycle. All cages were supplied with Sizzle Nest nesting
material (Datesand Ltd., UK) and cardboard enrichment
tubes (Datesand Ltd., UK). Mice had ad libitum access
to standard rodent diet (SDS, UK) and water. Mice were
acclimatised to the facility for at least 1 week before the
commencement of experimental work.
Middle cerebral artery occlusion (MCAO)
A total of 106 male C57BL/6 mice (Charles River La-
boratories, UK) aged 12–20 weeks (mean body weight
27.0 g; 22.5–32.1 g) were used for all stroke experiments.
For study 1 (Fig. 1a), the groups were sham + vehicle
(n = 10), sham + αCM (n = 10), stroke + vehicle (n = 12)
and stroke + αCM (n = 12). In study 2 (Fig. 1b), the
groups were sham + vehicle (n = 12), sham + αCM (n =
12), stroke + vehicle (n = 12) and stroke + αCM (n = 12).
For the quantification of lesion volume, additional 14
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mice (stroke + vehicle, n = 7; stroke + CM, n = 7) were
culled at 48 h. The groups were randomly assigned using
the random number function in Excel. All researchers
were blinded to the treatment group during surgery, be-
havioural assessment and all other analyses. This was
achieved by having an independent researcher conceal
treatment groups. Transient cerebral ischaemia was in-
duced using the intraluminal filament model of MCAO
as previously described [19]. In brief, animals were
anaesthetised with isoflurane (4% in 30% O2 and 70%
N2O), and an incision was made in the left common ca-
rotid artery. A 6-0 silicon-coated nylon filament (Doccol,
USA) was then inserted into the internal carotid artery
and advanced to occlude the middle cerebral artery. A
laser Doppler probe (Oxford Optronix, UK) was used to
confirm a reduction of cerebral blood flow. In study 1,
Fig. 1 Summary of stroke study timelines and behavioural tests. In the first study, a conditioned medium from IL-1α-primed mesenchymal stem
cells (αCM) was administered at the time of reperfusion by subcutaneous injection, then mice were recovered for 14 days (a). In the second
study, a conditioned medium was administered 24 h post-stroke (b). Mice were then recovered for 30 days to facilitate the assessment of post-
stroke anxiety and depressive-like behaviours at late time points. With the exception of open field, novelty-suppressed feeding and elevated zero
maze baseline behavioural assessments were conducted before stroke surgery
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the filament was withdrawn after 20 min to allow reper-
fusion. In study 2, the occlusion time was reduced to 15
min. In sham animals, the same procedure was per-
formed with the exception that the filament was ad-
vanced but withdrawn immediately. Throughout the
procedure, body temperature was monitored and main-
tained at 37 ± 0.5 °C using a homoeothermic blanket and
a rectal probe (Harvard Apparatus, UK). Buprenorphine
(0.05 mg/kg) was administered via subcutaneous injec-
tion at the time of surgery and at 24 h. Mice were
weighed daily for the first week post-stroke, given
mashed diet and administered with 0.5 ml saline daily
until body mass stabilised (usually days 3–4 post-stroke).
A 400-μl 10× concentrated αCM treatment or Mesen-
PRO (vehicle) was administered by subcutaneous injec-
tion at the time of reperfusion in study 1 and at 24 h
after MCAO in study 2. Animals were excluded from
the studies if occlusion was not successful (defined as <
70% reduction in cerebral blood flow) or exceeded hu-
mane end points in the IMPROVE guidelines [20]. De-
tails of all exclusions are listed in the “Results” section.
Behavioural assessment
Tunnel handling was employed as recommended by the
National Centre for the Replacement, Refinement & Re-
duction of Animals in Research (NC3Rs). Prior to the
baseline behavioural assessment, mice were habituated
to this handling method for 3 days. All behavioural tests
were run during the light phase (6 am to 6 pm) unless
otherwise stated. Mice underwent a battery of behav-
ioural tests (Fig. 1), conducted by a researcher blinded to
the treatment groups. All apparatus were cleaned thor-
oughly with 70% ethanol between animals to eliminate
olfactory cues. Importantly, in contrast to most preclin-
ical stroke studies that focus largely on sensorimotor
deficits, here we extend the battery of tests used to as-
sess post-stroke behaviour to include ethologically rele-
vant tests that might correlate with complications such
as depression and fatigue, commonly reported by stroke
survivors as the most debilitating.
Open field
Open field was conducted at 24 h post-stroke in study 1
to assess motor impairment and exploratory behaviour.
Mice were placed into the centre of a square Perspex
arena (450 × 450 × 200 mm) and allowed to explore
freely for 5 min. Distance travelled, time spent in differ-
ent zones and rotations were analysed live using ANY-
maze v4.9 software (Stoelting, USA).
28-point neurological score
The 28-point neurological scale (neuroscore) as previ-
ously described by Clark and colleagues [21] was per-
formed to assess sensorimotor recovery. In brief, 7 items
(body symmetry, gait, climbing, circling behaviour, front
limb symmetry, compulsory circling and whisker re-
sponses) were scored out of 4 where 0 is normal and 4
is significant impairment.
Rotarod
Rotarod has been widely used to evaluate motor recov-
ery after cerebral ischaemia [22]. Mice were placed on
an accelerating rotarod (Med Associates Inc., USA)
which gradually increased in speed from 4 to 40 rpm
over 5 min. Latency to fall or three passively accrued ro-
tations were recorded. A total of three trials were con-
ducted with at least 15 min inter-trial intervals, and the
mean was recorded and used for analysis. For baseline
measurements, mice were trained for three consecutive
days prior to stroke.
Burrowing behaviour
Burrowing behaviour was used to assess sickness behav-
iour after stroke. Burrowing tubes were made from 200
mm lengths of 68 mm diameter PVC downpipe as de-
scribed previously [23]. Mice were placed in individual
cages with a burrowing tube containing 150 g standard
rodent diet food pellets (SDS, UK). After 2 h, the food
remaining in the tubes was weighed and subtracted from
the initial weight (150 g) to calculate the mass burrowed.
Two baseline sessions were conducted at least 48 h apart
prior to MCAO. Mice which burrowed < 30 g at baseline
were excluded from the analysis.
Nest building
Nest building, a spontaneous home-cage behaviour, was
used as an assessment of well-being. Mice were placed
in individual cages containing 20 g of Sizzle Nest nesting
material (Datesand Ltd., UK) at least 1 h before the onset
of the dark cycle. Mice were left overnight, and nests
were scored in the morning after the onset of the light
cycle. The scoring system, adapted from Gaskill and col-
leagues [24], was as follows:
0. No manipulation of nesting material
1. No obvious nest site present (majority of nesting
material not contained to one quadrant of the cage)
2. Nest present but flat
3. Nest has raised walls ≤ 30 mm in height
4. Nest walls 31–49 mm in height
5. Nest walls ≥ 50 mm in height
Photographs were taken on a smartphone camera
(Xiaomi, China). Each quadrant of the nests was scored
by an observer blinded to the group and time point then
averaged. Blinding was conducted by asking an inde-
pendent researcher to rename the file.
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Elevated zero maze
The elevated zero maze (San Diego Instruments, USA)
apparatus consisted of a grey plastic 600 mm diameter
annular runway elevated 600 mm above the floor. This is
divided into four quadrants: two closed arms with 15-
mm walls and two open arms. Mice were introduced
into one of the closed arms and allowed to explore for 5
min. ANY-maze software was used again for live
tracking.
Novelty-suppressed feeding
Novelty-suppressed feeding is widely used to assess anx-
iety and screen novel anti-depressants [25]. This test
measures hyponeophagia, inhibition of feeding in re-
sponse to a novel environment. The apparatus consisted
of a square Perspex arena (450 × 200 × 450 mm) with a
35-mm culture dish (Corning, UK) containing 1 g of
sweetened condensed milk (Aldi, Germany) in the
centre. Mice were introduced into a corner and allowed
to explore for 5 min. A digital USB 2.0 CMOS camera
(Stoelting, USA) positioned directly above the apparatus
connected to a laptop with ANY-maze version 6.0
(Stoelting, USA) was used for video recording and live
tracking. Latency to approach food was timed manually
from the videos by an observer blinded to the time point
and treatment group. The dish was weighed after testing
to calculate the mass of the food eaten.
Social interaction and social preference test
The social interaction and social preference test appar-
atus consisted of a Plexiglas box with three 200 × 400 ×
220 mm chambers (Ugo Basile, Italy). The two outer
chambers, which could be isolated from the central
chamber by insertion of two removable doors, contained
custom PET interaction cups (diameter 65 mm, height
195 mm, 10 mm holes to allow sniffing). On the 2-day
preceding baseline assessment, each cage was allowed to
explore the empty apparatus for 5 min to habituate. On
the day of testing, mice were placed in the central cham-
ber for 5 min for further habituation. During this time, a
non-littermate control mouse (stranger 1) of the same
sex and background was placed into one of the inter-
action cups. The position was randomised between the
trials using a smartphone application (Random Number,
Saranomy). The doors were then removed, and the test
mouse was allowed to explore for 5 min (session I). For
the next session, a second control mouse (stranger 2)
was placed in the other chamber, and the test mouse
was allowed to explore for a further 5 min (session II).
ANY-maze facilitated video recording and live tracking.
Interaction time with the stranger mice was scored
manually from videos by an observer blinded to the time
point and treatment group using an online timer (http://
jackrrivers.com/program/). Interaction was defined as a
direct contact or stretching of the body within 30–50
mm around the cage.
Magnetic resonance imaging
At 48 h post-stroke, animals in study 1 were anaesthe-
tised with 4% isoflurane and T2-weighted scans were
conducted on Bruker Advance III console (Bruker Bios-
pin Ltd., UK) using a 7-T magnet. A total of 14 serial
slices with a thickness of 1 mm were acquired. Lesion
volumes were measured using ImageJ and corrected
from oedema.
Quantification of lesion volume
At 48 h, a sub-cohort of animals in study 2 was perfused
intracardially with 0.9% saline followed by 4% parafor-
maldehyde (PFA), in 0.1 M phosphate buffer (PB). The
brains were removed and post-fixed in 4% PFA for 24 h
then transferred to 30% sucrose before being snap-
frozen in isopentane. The sections were cut at a thick-
ness of 30 μm using a freezing sledge microtome and
mounted on gelatin-coated slides. The sections were
then stained with cresyl violet and coverslipped with
DPX mounting medium (Sigma-Aldrich, UK). Lesion
volumes were then measured using ImageJ and cor-
rected for oedema.
Immunohistochemistry
Mice were perfused intracardially as described above. The
brains were removed, post-fixed in 4% PFA and cut into
2-mm sections before being processed and embedded in
paraffin. The sections were cut at 5 μm using a rotary
microtome (Leica, Germany) and mounted on Superfrost
Plus slides (Thermo Fisher, UK). After deparaffinisation
and rehydration with xylene and ethanol, antigen retrieval
was conducted by heating the slides in Tris-EDTA buffer
(10mM Tris base, 1 mM EDTA solution, 0.05% Tween
20, pH 9.0) in a water bath at 95 °C for 30min. The slides
were then loaded in Sequenza racks (Thermo Fisher, UK)
was washed with TBST (Tris-buffered saline, 0.1% Tween
20). The slides were incubated in primary antibodies di-
luted in 1% bovine serum albumin (BSA) TBST for 1 h at
room temperature. Primary antibodies used were GFAP
(1:2000, ab7260) and iba1 (1:2000, ab178846). The slides
were incubated with biotinylated anti-rabbit secondary
antibody (1:200, Vector Laboratories, UK) followed by
Vectastain ABC and Vector Red substrate (Vector Labora-
tories, UK). The sections were then counterstained with
haematoxylin and mounted with DPX (Merck, UK).
Brightfield images were acquired on a 3D-Histech
Pannoramic-250 microscope slide-scanner using a × 20/
0.30 Plan Achromat objective (Zeiss, Germany). The ipsi-
lateral cortex and striatum were defined as the regions of
interest (ROI). Images were acquired using Case Viewer
software (3D-Histech, Hungary), then total area of positive
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staining was quantified using ImageJ by an experimenter
blinded to the treatment group.
For immunofluorescence, following antigen retrieval as
above slides were incubated in primary Ki67 (1:200,
BD550609) and NeuN (1:1000, ab177487) at 4 °C over-
night. The slides were then incubated in biotinylated
anti-mouse (1:500, Vector Laboratories, UK) and Alexa
Fluor™ 647 anti-rabbit (1:500) for 1 h 30. A tyramide
super boost kit (B40933) was used to amplify Ki67 signal
as per the manufacturer’s protocol. The sections were
counterstained using DAPI (1 μg mL−1, 10 min, D9542)
and mounted using ProLong® Gold Antifade Mountant
(Thermo Fisher, UK). Images were collected on a Zeiss
Axioimager.D2 upright microscope using a × 20/0.8 Plan
Apochromat objective and captured using a Coolsnap
HQ2 camera (Photometrics) through Micromanager
software v1.4.23. Images were then processed and ana-
lysed using ImageJ by an experimenter blinded to the
treatment group.
Data and statistical analysis
All data are expressed as mean ± standard deviation
(SD). For the stroke studies, a power calculation of
the primary measure of performance in the burrowing
behaviour task was conducted with previously ac-
quired data using an online calculator (https://jacka-
uty.com/power-calculator/). Using a mean of 81.2, a
SD of 25.9, an alpha of 0.05 and a power of 0.8, an n
of 8 was calculated to detect a 60% improvement. Ac-
counting for a 30% attrition rate, an n of 12 was
chosen. Statistical analysis was conducted in RStudio
Version 1.1.463 (https://www.rstudio.com) using the
car, lme4 and lsmeans packages. Assumptions were
assessed graphically, and if necessary, data were trans-
formed. Multilevel modelling was used to analyse
body mass, burrowing and rotarod data. If statistical
significance was achieved (p < 0.05), Holm-Sidak post
hoc tests were then conducted. Open field, elevated
zero maze, novelty-suppressed feeding, social inter-
action and immunohistochemical data were analysed
by two-way ANOVA followed by Holm-Sidak post
hoc tests. All remaining data analysis was conducted
using GraphPad Prism 7.01 (GraphPad Software Inc.,
USA). Nest building and neuroscore data were ana-
lysed by Mann-Whitney tests, and lesion volumes
were analysed by Student’s t test. To determine if
mice showed preference for interacting with a stran-
ger mouse over an empty cup and a novel stranger
over a familiar stranger in the social interaction test,
one-sample t tests were used to compare the percent-
age of interaction time to a theoretical mean of 50%.
GraphPad Prism 7.01 was used for presenting all data,
and statistical significance was defined as p < 0.05.
Results
Conditioned medium treatment at time of stroke has a
neuroprotective effect and promotes improvements in
measures of well-being
In study 1, two mice from the stroke + αCM group were
excluded due to subarachnoid haemorrhage and one
exceeded the humane end point of > 20% body mass loss
and was culled early. In the stroke + vehicle group, one
mouse was culled early due to weight loss and two were
excluded due to < 70% Doppler drop. The excluded ani-
mals were not replaced. There were no postoperative
complications in the sham-operated groups.
Subcutaneous administration of conditioned medium
derived from IL-1α-primed MSCs (αCM) administered
at the time of reperfusion had a neuroprotective effect
leading to ~ 30% reduction in lesion volume (Fig. 2b).
This was associated with modest improvements in well-
being. There was an overall treatment effect in body
mass loss after MCAO (p = 0.022), and post hoc analysis
revealed significant differences between αCM- and
vehicle-treated mice at days 3, 5 and 7 post-stroke, with
αCM-treated animals losing less weight (Fig. 2c). In the
28-point neurological score, the stroke + αCM group
performed better than the stroke + vehicle group at day
2 post-MCAO but not at any subsequent time point
(Fig. 2d). In the open field task conducted at day 1 post-
stroke, there were no significant differences between the
treatment groups but there was a stroke effect in per-
centage of anti-clockwise rotations (p < 0.001, Fig. 2e)
showing MCAO-induced asymmetry. Furthermore, there
were also pronounced stroke effects in accelerating
rotarod (p < 0.0001, Fig. 2f) and burrowing behaviour
(p < 0.001, Fig. 2g). At day 3 post-stroke, αCM treatment
led to improved performance in the nest building task
after MCAO (p = 0.04), but by day 13, there was no sig-
nificant difference compared with the vehicle treatment
(p = 0.088, Fig. 2h).
At day 14, MCAO was associated with increased ex-
pression of microglial marker Iba1 in both the ipsilateral
cortex and striatum (p < 0.0001, Additional file 2: Figure
S2), but there were no differences between the stroke +
vehicle and stroke + αCM groups. Similarly, MCAO also
led to increased GFAP expression, an astrocyte marker
(p < 0.0001, Additional file 2: Figure S2), but there was
no treatment effect.
Conditioned medium treatment promotes recovery
independently of neuroprotection
From stroke study 2, one mouse from the sham + αCM
group was excluded due to post-operative complications.
From the stroke + vehicle group, two mice were ex-
cluded due to subarachnoid haemorrhage and a further
two animals were culled early for reaching humane end
points. A total of three mice in the stroke + αCM group
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were also culled for animal welfare reasons. As in study
1, the excluded mice were not replaced. The overall
mortality rate for MCAO in both studies was 19%.
In this study, the administration of αCM derived from
IL-1α-primed MSCs was delayed to 24 h post-stroke.
We believe this time point to be outside the window for
neuroprotection, and this was confirmed by the lack of
effect on lesion volume at 48 h (Additional file 3: Figure
S3). While there was no overall treatment effect (p =
0.058), there were significant differences in body mass
between αCM-treated stroke mice and vehicle-treated
animals at days 5, 6 and 7 between the groups, αCM
treatment leading to increased weight gain (Fig. 3a).
From day 7 post-stroke onwards, αCM treatment was
associated with significant improvements in 28-point
neurological scores compared with vehicle-treated ani-
mals (Fig. 3b). In similarity with the data in the first
study, there was no treatment effect in the burrowing
behaviour task but there was an acute stroke effect at
day 2 (p = 0.004, Fig. 3c). At day 9 post-stroke, αCM
treatment was associated with improved performance in
the nest building task (p = 0.0245, Fig. 3d).
Fig. 2 Effect of αCM treatment at the time of stroke on lesion volume and functional recovery. Representative T2-weighted MRI scans (a)
conducted at day 2 post-stroke and quantification (b). Changes in body mass over 14 days post-stroke expressed as percentage of baseline (c)
and 28-point neurological score (d). Percentage of anti-clockwise rotations in the open field test at 24 h post-stroke (e) and latency to fall in
accelerating rotarod (f). Burrowing behaviour (g) and nest building (h) tests were used as measures of well-being. Neuroscore and nest building
data were expressed as median ± IQR. All other data were expressed as mean ± SD. Sham + vehicle, n = 10; sham + αCM, n = 10; stroke + vehicle,
n = 9; stroke + αCM, n = 9. *p < 0.05
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At day 30, MCAO was associated with increased
microglial Iba1 expression in both the ipsilateral cortex
and striatum (p < 0.0001, Additional file 4: Figure S4),
but there was no treatment effect. MCAO also led to in-
creased GFAP expression in the cortex and striatum
(p = 0.0002 and p < 0.0001, respectively, Additional file 4:
Figure S4). Additionally, no differences between the
groups were observed in Ki67 staining in the subventri-
cular zone, infarct and dentate gyrus (Additional file 4:
Figure S4).
MCAO induces chronic anxiety-like behaviours
In the novelty-suppressed feeding test conducted at day
22 post-stroke, MCAO was associated with increased la-
tency to eat (p = 0.043, Fig. 4a) and decreased food eaten
(p = 0.017, Fig. 4a) which is indicative of anxiety-like be-
haviour. Unexpectedly, there was also a treatment effect
with αCM being associated with increased consumption
of the food (p = 0.014, Fig. 4b). In the elevated zero maze
test at day 28, stroke spent more time in the open arms
of the arena (p < 0.001, Fig. 4c) and displayed increased
motor activity compared with sham animals (p = 0.011,
Fig. 4d). The data from the social interaction and social
preference test were highly variable, and there were no
differences in the interaction time between the stroke +
αCM and stroke + vehicle groups at any time point
(Additional file 5: Figure S5).
Discussion
In this study, we provide a detailed in vivo investigation
of the efficacy of preconditioning as a strategy to
enhance the therapeutic potential of MSCs. More specif-
ically, we demonstrate for the first time that subcutane-
ous administration of IL-1α-primed MSC-derived CM
(αCM) at the time of reperfusion had a significant neu-
roprotective effect and provided modest improvements
in measures of well-being in a mouse model of focal
cerebral ischaemia. We then further show that delaying
the administration of αCM to 24 h post-stroke led to im-
proved functional recovery, evidenced by increased nest
building scores at day 9 and significantly improved
neurological scores from day 7 onwards, independently
of neuroprotection. Overall, our work indicates that the
IL-1-primed MSC secretome could be a useful novel
acellular therapy for stroke.
Our results suggest the MSC secretome promotes
functional recovery independently of neuroprotection.
Since the CM from MSCs rather than the cells them-
selves is injected, the observed effects must be paracrine.
In support of this, a previous study showed that intrana-
sal administration of umbilical cord-derived MSC condi-
tioned medium beginning at 24 h was shown to promote
recovery in a rat MCAO model but did not lead to im-
provements in lesion volume [11]. Delaying the adminis-
tration of MSCs to 3 days [26], 4 days [27] and 2 weeks
post-stroke [28] is also described as effective further sug-
gesting neuroprotection is not the main mechanism of
action. As our primary aim was to assess the efficacy of
CM, elucidating the mechanisms of action was out of
the scope of this study. Indeed, determining the mecha-
nisms from in vivo studies as described here is extremely
challenging, as several mediators are involved in
Fig. 3 Effect of αCM treatment at 24 h on functional recovery after stroke. Changes in body mass (a) and 28-point neurological score (b) over 30
days post-stroke. Performance in burrowing behaviour (c) and nest building (d) tests. Neuroscore and nest building data were expressed as
median ± IQR. All other data were expressed as mean ± SD. Sham + vehicle, n = 12; sham + αCM, n = 11; stroke + vehicle, n = 8; stroke + αCM, n = 9.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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promoting recovery which will have different pharmaco-
logical effects. For example, neutralising BDNF did not
completely abolish the observed improvements in func-
tional deficit following MSC administration in a rat
model of ischaemic stroke [28]. Overexpression of glial-
derived neurotrophic factor (GDNF), angiopoietin-1
(Ang-1), HGF, FGF1 and PIGF has been shown to fur-
ther increase recovery compared with non-modified
MSCs suggesting these mediators are also involved and
highlighting the significant redundancy that exists in
such approaches [29–32]. We previously reported G-
CSF was a crucial mediator involved in the observed
anti-inflammatory effect of αCM in our in vitro cell cul-
ture studies, as observed by reduced IL-6 and tumour
necrosis factor-alpha (TNF-α) secretion from
lipopolysaccharide-stimulated microglia [17]. A logical
follow-on study therefore might be to determine the ef-
fects of neutralising G-CSF in the αCM on functional re-
covery after MCAO. However, while this might
demonstrate some involvement of G-CSF, it is unlikely
to completely abolish the effects of priming, as we saw
only a partial effect of G-CSF inhibition in our in vitro
studies and also identified the expression of several other
potential mediators in the αCM [17]. Though never
studied in the context of stroke, TNFα-stimulated gene-
6 (TSG-6) has been proposed as a key mediator released
from MSCs that can mediate beneficial effects [33], and
future studies should consider exploring this further in
relation to the actions of the primed MSC-derived CM
presented in this study. We see no change in the expres-
sion of Iba1 or GFAP with CM treatment which suggests
that alterations in glial function are probably not the
mechanism involved in CM actions. Similarly, Ki67 ex-
pression is unaltered between the vehicle- and CM-
treated animals, ruling out any paracrine effects of the
CM on neurogenesis, at least under the conditions
tested. A multiplex analysis of inflammatory cytokines in
the plasma was performed at 2 and 7 days post-stroke to
Fig. 4 Performance in tests of anxiety and depressive-like behaviours at late time points post-stroke. Latency to eat food (a) and mass of food
eaten (b) in the novelty-suppressed feeding task at day 22 post-stroke. Time spent in open arms (c) and total distance travelled in the elevated
zero maze at day 28 (d). Data were expressed as mean ± SD. Sham + vehicle, n = 12; sham + αCM, n = 11; stroke + vehicle, n = 8;
stroke + αCM, n = 9
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determine whether changes in peripheral inflammation
might be responsible for the CM effects, but no consist-
ent differences were observed between the vehicle- and
CM-treated groups (data not shown). Despite the lack of
mechanism for the CM effect, the overriding primary
objective in this study was to provide proof of concept
of the therapeutic potential of CM from primed MSCs
in stroke, which we believe has been successfully
achieved.
In our future work, we would like to explore the
mechanisms of action of CM. We acknowledge the
chronic end points used in this current work (days 14
and 30) were not optimal for IHC analysis. For example,
angiogenesis begins within the first few days with VEGF
upregulation in the infarct occurring between 6 and 24 h
after MCAO [34]. One potential mechanism to explore
is the possible role of cell adhesion molecules (CAMs) in
CM-mediated recovery. While not extensively investi-
gated, one study reported that MSC transplantation re-
duced endothelial ICAM-1 expression which may have
been associated with reduced blood-brain barrier disrup-
tion [35]. Future studies should therefore investigate the
contribution of both vascular- and non-vascular-
associated CAMs in the observed effects of IL-1α-
primed MSCs. Although we report for the first time that
CM from IL-1α-primed MSCs promotes improved out-
comes after ischaemic stroke, we do acknowledge that a
limitation of this work is the lack of comparison between
CM from primed and unprimed MSCs. However, our
previously described in vitro cell culture studies clearly
demonstrate the added benefit of the IL-1α priming, and
our ongoing parallel studies comparing the intra-arterial
administration of primed and unprimed MSCs confirm
that priming enhances efficacy (Wong et al. unpublished
observations).
Mood disorders after stroke are very common and can
cause more disability than motor complications. Around
18% of stroke patients experience anxiety [36] and 30–
50% are diagnosed with depression [37], both of which
are associated with poorer outcomes after rehabilitation.
Similarly, fatigue leads to poorer quality of life, and a re-
cent systematic review demonstrated that 50% of stroke
patients report fatigue [38]. Despite this evident clinical
problem, there is a paucity of literature assessing the ef-
ficacy of therapies on non-motor complications in pre-
clinical models of stroke. For this reason, we employed a
battery of behavioural tests to assess well-being, depres-
sive and anxiety-like behaviours. To the best of our
knowledge, we are the first group to implement such
burrowing and nest building tests in a rodent stroke
model. Burrowing behaviour has previously been used in
mouse models of systemic inflammation, prion disease,
cytotoxic hippocampal lesions and Alzheimer’s disease
[39–42]. In this study, we demonstrated that stroke
induced pronounced deficits in the burrowing task
acutely at days 2 and 3 but not at later time points. Bur-
rowing behaviour could therefore be a useful test for
assessing post-stroke sickness behaviour. In similarity
with burrowing, nest building is a spontaneous home-
cage behaviour. Both male and female mice will build
nests for thermoregulation [43]. Nest building has previ-
ously been used to assess well-being in a number of dis-
ease models [44] but not cerebral ischaemia. In this
study, we observed disruptions in the nest building be-
haviour from day 3 to 9 post-stroke in vehicle-treated
controls which was partially rescued by αCM. Therefore,
nest building appears to be a sensitive test for assessing
the efficacy of new treatments on well-being after stroke.
Here, we reported that MCAO induced anxiety-like
behaviours from day 22 post-stroke onwards. This is in
support of a previous study which showed increased la-
tency to eat in the novelty-suppressed feeding test at 14
weeks post-stroke in a mouse MCAO model and at 19
days following endothelin-induced prefrontal cortex le-
sion [45]. While we reported increased time spent in in
the open arm of the elevated zero maze in contrast to
what has been previously reported [45–47], this could be
due to hyperactivity. Hyperactivity has been observed as
late as 8 weeks after MCAO in mice [48].
Conclusions
In summary, our results demonstrate for the first time
that systemic administration of CM from IL-1α-primed
MSCs promotes improvements in recovery in a mouse
model of cerebral ischaemia independently of neuropro-
tection. While there is much research that needs to fully
elucidate the mechanisms of action and define which
mediators are essential in promoting repair, the IL-1-
primed MSC secretome holds much potential as an acel-
lular therapy for the treatment of ischaemic stroke.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13287-020-1560-y.
Additional file 1: Figure S1. Characterisation of MSCs. Flow cytometry
showing positive staining for MSC surface markers CD90, CD105 and
CD73 (A). Cells were negative for CD34, CD11b, CD19, CD45 and HLA-DR
(A). MSCs were successfully differentiated down adipogenic lineages as
shown by oil red staining for lipid deposition (B). Osteogenic differenti-
ation was evidenced by positive alizarin staining for calcium deposits and
toluidine blue staining for cartilage showed differentiation into chondro-
cytes (B). Scale bars are 25, 100 and 500 μm respectively.
Additional file 2: Figure S2. Iba1 and GFAP immunohistochemistry at
day 14 post-stroke. There were no treatment effects but stroke led to a
significant increase in Iba1 expression (p<0.0001) in both the ipsilateral
cortex and striatum (A). Representative 20x brightfield images of Iba1
staining (B). Stroke also led to increased GFAP expression (p<0.0001) in
the ipsilateral cortex and striatum (C-D). Scale bars = 100 μM. All data
expressed as mean ± SD. n=4-7. Data analysis was performed by two-
way ANOVA and Holm-Sidak post hoc tests.
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Additional file 3: Figure S3. Lesion volumes at 48 h post-stroke from
study 2. Data expressed as mean ± SD. Stroke + vehicle, n=7; stroke +
αCM, n=6.
Additional file 4: Figure S4. Immunohistochemistry at day 30 post-
stroke. Quantification and representative 20x brightfield images for iba1
(A) and GFAP (B). Ki67 staining in the subventricular zone (SVZ), infarct
and dentate gyrus (C). Scale bars = 500 μM. All data expressed as mean
± SD. n=4-12.
Additional file 5: Figure S5. Social interaction and social preference at
baseline and post-stroke. At baseline, all groups showed preference for
interacting with a novel stranger versus an empty cup (A). However, in
session 2 the stroke + αCM did not show a preference for the more
novel stranger 2. At day 23 post-stroke, there was a treatment effect in
session 1 but not session 2 (B). Session 2 at day 29 post-stroke was the
only time point at which the stroke + αCM showed preference for the
novel stranger (C). Data expressed as percentage of time spent with
stranger 1 versus empty cup (session 1) and time spent with more novel
stranger 2 versus stranger 1 (session 2). Data expressed as mean ± SD.
Sham + vehicle, n=12; sham + αCM, n=11; stroke + vehicle, n=8; stroke +
αCM, n=9 *, p<0.05.
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